|
29 Companies |
|
28 Products |
|
28 Products |
|
27 Mechanisms of Action |
|
0 Trials |
|
447 News |
|
| «12345678910» |
- Trial completion, Combination therapy: Microneedling Plus the Universal Peel For Acne Scarring (clinicaltrials.gov) - Feb 21, 2016
P=N/A, N=15, Completed, Sponsor: Englewood Hospital and Medical Center
Active, not recruiting --> Completed
- ||| adapalene/benzoyl peroxide / Generic mfg.
Trial completion, Enrollment change: PUMP-it: Application of Epiduo(R) PUMP in Daily Practice in Patients With Inflammatory Acne (clinicaltrials.gov) - Feb 17, 2016
P=N/A, N=1388, Completed, Sponsor: Galderma Laboratorium GmbH
Active, not recruiting --> Completed Enrolling by invitation --> Completed | N=2000 --> 1388
- ||| acebilustat (CTX-4430) / Celtaxsys
Enrollment closed: CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris (clinicaltrials.gov) - Feb 11, 2016
P2, N=124, Active, not recruiting, Sponsor: Celtaxsys, Inc.
Enrolling by invitation --> Completed | N=2000 --> 1388 Recruiting --> Active, not recruiting
- |||||||||| berdazimer sodium (SB204) / Sato Pharma, Novan
New P3 trial: P3 Study in Acne Comparing Once Daily SB204 and Vehicle (clinicaltrials.gov) - Feb 3, 2016
P3, N=1300, Not yet recruiting, Sponsor: Novan, Inc.
- ||| acebilustat (CTX-4430) / Celtaxsys
Enrollment change: CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris (clinicaltrials.gov) - Feb 2, 2016
P2, N=123, Recruiting, Sponsor: Celtaxsys, Inc.
Recruiting --> Active, not recruiting N=156 --> 123
- Trial completion, HEOR: Effect of Acne Vulgaris on Quality of Life of Teenagers Compared to Parent Perceived Effect on Quality of Life (clinicaltrials.gov) - Jan 28, 2016
P=N/A, N=60, Completed, Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
N=156 --> 123 Active, not recruiting --> Completed
- || berdazimer sodium (SB204) / Sato Pharma, Novan
Enrollment closed: A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204 (clinicaltrials.gov) - Jan 27, 2016
P1, N=56, Active, not recruiting, Sponsor: Novan, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Humira (adalimumab) / AbbVie
Trial primary completion date: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Jan 26, 2016
P3, N=540, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Sep 2016
- Pliaglis (lidocaine and tetracaine topical cream 7%/7%) / Galderma
Trial completion: OPTICA: 7% Lidocaine/7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream (clinicaltrials.gov) - Jan 20, 2016
P4, N=30, Completed, Sponsor: Erasmus Medical Center
Trial primary completion date: Mar 2016 --> Sep 2016 Recruiting --> Completed
- B244 topical / AOBiome
New P1/2 trial: A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris (clinicaltrials.gov) - Jan 15, 2016
P1/2, N=36, Recruiting, Sponsor: AOBiome LLC
- ||||| XEN-801 / Xenon
New P1/2 trial: A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel (clinicaltrials.gov) - Jan 14, 2016
P1/2, N=198, Recruiting, Sponsor: Xenon Pharmaceuticals Inc.
- Seysara (sarecycline) / Paratek, Almirall
New P3 trial: SC1401: Study to Evaluate the Efficacy and Safety of 1.5 mg/kg/Day of Sarecycline vs Placebo in the Treatment of Acne Vulgaris (clinicaltrials.gov) - Jan 11, 2016
P3, N=20, Recruiting, Sponsor: Sadick Research Group
- ||| benzoyl peroxide/clindamycin / Generic mfg.
Enrollment closed: DUAC (clinicaltrials.gov) - Jan 6, 2016
P4, N=351, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Not yet recruiting --> Active, not recruiting
- New P4 trial: Chromogenix: A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris (clinicaltrials.gov) - Jan 6, 2016
P4, N=30, Not yet recruiting, Sponsor: Sadick Research Group
- |||| Seysara (sarecycline) / Paratek, Almirall
Trial primary completion date: Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne (clinicaltrials.gov) - Dec 29, 2015
P3, N=1000, Recruiting, Sponsor: Warner Chilcott
Not yet recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Jul 2016
- |||| Seysara (sarecycline) / Paratek, Almirall
Trial primary completion date: Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne (clinicaltrials.gov) - Dec 29, 2015
P3, N=1000, Recruiting, Sponsor: Warner Chilcott
Trial primary completion date: Mar 2016 --> Jul 2016 Trial primary completion date: Mar 2016 --> Jul 2016
- ||||||| benzoyl peroxide/clindamycin / Generic mfg., clindamycin phosphate / Generic mfg.
Trial completion: To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris. (clinicaltrials.gov) - Dec 14, 2015
P3, N=1100, Completed, Sponsor: Glenmark Pharmaceuticals Ltd. India
Trial primary completion date: Mar 2016 --> Jul 2016 Recruiting --> Completed
- Enrollment change, Trial withdrawal: Efficacy of Handheld Acne Heat Device (clinicaltrials.gov) - Dec 4, 2015
P4, N=0, Withdrawn, Sponsor: University of British Columbia
Recruiting --> Completed N=20 --> 0 | Suspended --> Withdrawn
- New trial, Surgery: The Incidence and Incubation Period of False Positive Cultures in Shoulder Surgery (clinicaltrials.gov) - Nov 14, 2015
P=N/A, N=100, Enrolling by invitation, Sponsor: Methodist Sports Medicine
- ||||| New P2 trial: A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris (clinicaltrials.gov) - Nov 14, 2015
P2, N=500, Recruiting, Sponsor: Braintree Laboratories
- pamidronate disodium / Generic mfg.
Enrollment closed: Efficacy of Bisphosphonates in Patients With Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome (clinicaltrials.gov) - Nov 11, 2015
P1, N=30, Active, not recruiting, Sponsor: Peking Union Medical College Hospital
N=20 --> 0 | Suspended --> Withdrawn Not yet recruiting --> Active, not recruiting
- isotretinoin / Generic mfg., adapalene / Generic mfg.
Trial completion, Enrollment change: The Lipid Profile of the Skin Surface in Acne (clinicaltrials.gov) - Nov 5, 2015
P=N/A, N=30, Completed, Sponsor: University of California, Davis
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=45 --> 30
- ||| benzoyl peroxide/clindamycin / Generic mfg., clindamycin phosphate / Generic mfg.
New P1 trial: A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin (clinicaltrials.gov) - Nov 3, 2015
P1, N=1000, Completed, Sponsor: Taro Pharmaceuticals USA
- ||||| omiganan (CLS001) / Maruho
New P2 trial: A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris (clinicaltrials.gov) - Oct 22, 2015
P2, N=320, Recruiting, Sponsor: Cutanea Life Sciences, Inc.
- | ingenol disoxate (LEO 43204) / LEO Pharma
New P2 trial: Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne (clinicaltrials.gov) - Oct 22, 2015
P2, N=40, Not yet recruiting, Sponsor: LEO Pharma
- ||| berdazimer sodium (SB204) / Sato Pharma, Novan
New P1 trial: A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204 (clinicaltrials.gov) - Oct 22, 2015
P1, N=56, Recruiting, Sponsor: Novan, Inc.
- ||| benzoyl peroxide/clindamycin / Generic mfg., clindamycin phosphate / Generic mfg.
New P1 trial: A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton (clinicaltrials.gov) - Oct 22, 2015
P1, N=844, Completed, Sponsor: Taro Pharmaceuticals USA
- ||||||| tazarotene topical / Generic mfg.
Trial completion: Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris (clinicaltrials.gov) - Oct 19, 2015
P3, N=1741, Completed, Sponsor: G & W Laboratories Inc.
Active, not recruiting --> Completed | N=45 --> 30 Recruiting --> Completed
- |||| Trial completion: A Study to Evaluate the Clinical Effect of Daily Next Science (clinicaltrials.gov) - Oct 15, 2015
P1/2, N=68, Completed, Sponsor: Next Science TM
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Ultherapy (clinicaltrials.gov) - Oct 9, 2015
P=N/A, N=20, Completed, Sponsor: Ulthera, Inc
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Trial primary completion date: Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases (clinicaltrials.gov) - Sep 30, 2015
P=N/A, N=22061, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Mar 2016
- |||| Seysara (sarecycline) / Paratek, Almirall
Trial primary completion date: Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne (clinicaltrials.gov) - Sep 24, 2015
P3, N=1000, Recruiting, Sponsor: Warner Chilcott
Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Oct 2015 --> Mar 2016
- |||| Seysara (sarecycline) / Paratek, Almirall
Trial primary completion date: Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne (clinicaltrials.gov) - Sep 24, 2015
P3, N=1000, Recruiting, Sponsor: Warner Chilcott
Trial primary completion date: Oct 2015 --> Mar 2016 Trial primary completion date: Oct 2015 --> Mar 2016
- ||||| benzoyl peroxide/clindamycin / Generic mfg.
New P4 trial: DUAC (clinicaltrials.gov) - Sep 23, 2015
P4, N=350, Not yet recruiting, Sponsor: GlaxoSmithKline
- pamidronate disodium / Generic mfg.
New P1 trial: Efficacy of Bisphosphonates in Patients With Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome (clinicaltrials.gov) - Sep 9, 2015
P1, N=30, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- || Enrollment change: Risk Minimisation Study for Diane-35 and Its Generics (clinicaltrials.gov) - Aug 24, 2015
P=N/A, N=500, Recruiting, Sponsor: Bayer
Trial primary completion date: Oct 2015 --> Mar 2016 N=34 --> 500
- Pliaglis (lidocaine and tetracaine topical cream 7%/7%) / Galderma
Trial primary completion date: OPTICA: 7% Lidocaine/7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream (clinicaltrials.gov) - Aug 21, 2015
P4, N=30, Recruiting, Sponsor: Erasmus Medical Center
N=34 --> 500 Trial primary completion date: May 2015 --> Oct 2015
- Trial primary completion date: Ultherapy (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: Ulthera, Inc
Trial primary completion date: May 2015 --> Oct 2015 Trial primary completion date: Apr 2015 --> Aug 2015
- |||| berdazimer sodium (SB204) / Sato Pharma, Novan
Trial completion: P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris (clinicaltrials.gov) - Aug 20, 2015
P2, N=200, Completed, Sponsor: Novan, Inc.
Trial primary completion date: Apr 2015 --> Aug 2015 Active, not recruiting --> Completed
- | New P4 trial: 8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne (clinicaltrials.gov) - Aug 17, 2015
P4, N=20, Completed, Sponsor: Stiefel, a GSK Company
- Trial primary completion date: UVA1 Light for Scleroderma and Similar Conditions (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=23, Terminated, Sponsor: University of Michigan
Active, not recruiting --> Completed Trial primary completion date: May 2011 --> Jul 2003
- Enrollment change: Risk Minimisation Study for Diane-35 and Its Generics (clinicaltrials.gov) - Aug 4, 2015
P=N/A, N=34, Recruiting, Sponsor: Bayer
Trial primary completion date: May 2011 --> Jul 2003 N=27 --> 34
- || Enrollment change: Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases (clinicaltrials.gov) - Jul 29, 2015
P=N/A, N=22061, Active, not recruiting, Sponsor: Bayer
N=27 --> 34 N=10000 --> 22061
- || isotretinoin / Generic mfg.
Trial primary completion date: Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment (clinicaltrials.gov) - Jul 20, 2015
P=N/A, N=250, Recruiting, Sponsor: Duke University
N=10000 --> 22061 Trial primary completion date: Jun 2015 --> Dec 2016
- ||||| finasteride / Generic mfg.
New P2 trial: Finasteride Treatment of Severe Nodulocystic Acne (clinicaltrials.gov) - Jul 20, 2015
P2, N=180, Recruiting, Sponsor: Elorac, Inc.
- Trial primary completion date: Impact of the M22-IPL Acne Filter on Acne Vulgaris (clinicaltrials.gov) - Jul 16, 2015
P=N/A, N=20, Recruiting, Sponsor: Lumenis Ltd.
Trial primary completion date: Jun 2015 --> Dec 2016 Trial primary completion date: Jun 2015 --> Jan 2016
- isotretinoin / Generic mfg.
New P1 trial: A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition (clinicaltrials.gov) - Jul 15, 2015
P1, N=36, Completed, Sponsor: GlaxoSmithKline
- Enrollment closed, Trial primary completion date: Multiple Arm Study of Sebacia Microparticles in the Treatment of Acne Vulgaris (clinicaltrials.gov) - Jul 15, 2015
P=N/A, N=310, Active, not recruiting, Sponsor: Sebacia, Inc.
Trial primary completion date: Jun 2015 --> Jan 2016 Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Oct 2015
- Humira (adalimumab) / AbbVie
Trial primary completion date: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Jul 14, 2015
P3, N=540, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Oct 2015 Trial primary completion date: Jul 2015 --> Mar 2016
- Enrollment open, Trial primary completion date: Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris (clinicaltrials.gov) - Jul 14, 2015
P=N/A, N=300, Recruiting, Sponsor: Sebacia, Inc.
Trial primary completion date: Jul 2015 --> Mar 2016 Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Nov 2015